Items Tagged ‘Pancreatic Cancer’

March 18, 2019

Lynparza Delays Progression of BRCA-mutated Metastatic Pancreatic Cancer

By

Lynparza (olaparib) improves progression-free survival (PFS) when used to treat BRCA-mutated pancreatic cancer and appears to represent a new treatment option for this hard to treat cancer. (1-4) About BRCA Mutated Pancreatic Cancer Pancreatic cancer has the worst survival rate of the most common cancers and less than seven percent of patients survive more than […]

View full entry

Tags: News, Pancreatic Cancer


February 28, 2019

Lynparza significantly delayed disease progression as 1st-line maintenance treatment in germline BRCA-mutated metastatic pancreatic cancer

By

Results from the trial showed a significant and clinically-meaningful improvement in progression-free survival (PFS) with Lynparza (olaparib) for the treatment of BRCA-mutated pancreatic cancer. POLO is a randomised, double-blinded, placebo-controlled trial exploring the efficacy of Lynparza tablets as 1st-line maintenance monotherapy in patients with germline BRCA-mutated (gBRCAm) metastatic adenocarcinoma of the pancreas (pancreatic cancer) whose […]

View full entry

Tags: News, Pancreatic Cancer


June 19, 2018

mFOLFIRINOX Found Superior to Gemzar for Treatment Surgically Resected Pancreatic Cancer

By

The results of a recently presented clinical study at the American Society of Clinical Oncology meetings last week suggest that more aggressive chemotherapy treatment improves outcomes compared to single agent Gemzar (gemcitabine) chemotherapy which has been a standard treatment for over a decade. About Pancreatic Cancer Pancreatic cancer is one of the deadliest forms of […]

View full entry

Tags: Chemotherapy, gemzar, mFOLFIRINOX, News, Pancreatic Cancer, treatment


April 18, 2018

First Interim Analysis in SEQUOIA Phase 3 Pancreatic Cancer Study

By

CancerConnect News: The first interim analysis of the SEQUOIA clinical study evaluating the novel immunotherapy drug pegilodecakin in patients with pancreatic cancer will continue to enroll patients based on The Data Monitoring Committee first interim analyses and recommendation. About Pancreatic Cancer Pancreatic cancer is one of the deadliest forms of cancer. Each year, approximately 43,000 people […]

View full entry

Tags: AM0010, clinical trials, immunotherapy, Interleukin-10, News, Pancreatic Cancer, pegilodecakin, Precision Cancer Medicine, treatment


March 5, 2018

Pamrevlumab Awarded “Fast Track” Development Status for Treatment of Patients with Locally Advanced Pancreatic Cancer

By

CancerConnect News: The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the anti-CTGF antibody, pamrevlumab, for the treatment of patients with locally advanced unresectable pancreatic cancer. This follows review of the Phase 2 clinical trial evaluating pamrevlumab in combination with gemcitabine and nab-paclitaxel and represents recognition by the FDA that pamrevlumab […]

View full entry

Tags: locally advanced, News, Pamrevlumab, Pancreatic Cancer, Precision Cancer Medicine, treatment


February 28, 2018

Larotrectinib Demonstrates 76 Percent Response Rate in TRK Fusion Cancers Including Pancreatic Cancer

By

CancerConnect News: Clinical data from three ongoing larotrectinib (LOXO-101) clinical trials in patients whose tumors harbor tropomyosin receptor kinase (TRK) fusions demonstrating a 76 percent confirmed objective response rate across tumor types, were published today in the New England Journal of Medicine after an initial summary presentation at the American Society of Clinical Oncology in […]

View full entry

Tags: larotrectinib, News, Pancreatic Cancer, Precision Cancer Medicine, treatment


December 26, 2017

Diagnosed with Pancreatic Cancer: 10 Tips on How to Get The Most From Your Doctor

By

1) Choose Your Doctor Carefully Surgeons, medical oncologists and radiation oncologists are the primary doctors involved with pancreatic cancer and often work in collaboration. Pick your primary oncologist carefully, rely on people you trust including nurses and other health care professionals who make help with recommendations.  Make sure your doctor is someone you feel comfortable […]

View full entry

Tags: News, Pancreatic Cancer


May 10, 2011

Afinitor Approved for Pancreatic Neuroendocrine Tumors

By

The US Food and Drug Administration has approved Afinitor® (everolimus) for the treatment of advanced pancreatic neuroendocrine tumors (PNET). Pancreatic neuroendocrine tumors are a relatively uncommon type of cancer that develops in the hormone-producing cells of the pancreas. Afinitor is an oral targeted therapy that works by inhibiting a protein known as the mammalian target […]

View full entry

Tags: Pancreatic Cancer, Stage IV Pancreatic Cancer, Stages I-III Pancreatic Cancer


March 31, 2009

Blood Type Linked to Risk of Pancreatic Cancer

By

Individuals with A, AB, or B blood types may have a higher risk of developing pancreatic cancer, according to the results of a study published in the Journal of the National Cancer Institute.[1] The pancreas is an organ that is surrounded by the stomach, small intestine, bile ducts (tubes that connect the liver to the […]

View full entry

Tags: Pancreatic Cancer